Literature DB >> 19283561

Early outcomes following low dose naltrexone enhancement of opioid detoxification.

Paolo Mannelli1, Ashwin A Patkar, Kathleen Peindl, Edward Gottheil, Li-Tzy Wu, David A Gorelick.   

Abstract

Although withdrawal severity and treatment completion are the initial focus of opioid detoxification, post-detoxification outcome better defines effective interventions. Very low dose naltrexone (VLNTX) in addition to methadone taper was recently associated with attenuated withdrawal intensity during detoxification. We describe the results of a seven-day follow-up evaluation of 96 subjects who completed inpatient detoxification consisting of the addition of VLNTX (0.125 or 0.250 mg per day) or placebo to methadone taper in a double blind, randomized investigation. Individuals receiving VLNTX during detoxification reported reduced withdrawal and drug use during the first 24 hours after discharge. VLNTX addition was also associated with higher rates of negative drug tests for opioids and cannabis and increased engagement in outpatient treatment after one week. Further studies are needed to test the utility of this approach in easing the transition from detoxification to various follow-up treatment modalities designed to address opioid dependence.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19283561      PMCID: PMC3190236          DOI: 10.1080/10550490902772785

Source DB:  PubMed          Journal:  Am J Addict        ISSN: 1055-0496


  42 in total

Review 1.  Opioid antagonists under heavy sedation or anaesthesia for opioid withdrawal.

Authors:  L Gowing; R Ali; J White
Journal:  Cochrane Database Syst Rev       Date:  2006-04-19

2.  In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone.

Authors:  J McCambridge; M Gossop; T Beswick; D Best; J Bearn; S Rees; J Strang
Journal:  Drug Alcohol Depend       Date:  2006-10-24       Impact factor: 4.492

3.  One-, three-, and six-month outcomes after brief inpatient opioid detoxification.

Authors:  M A Chutuape; D R Jasinski; M I Fingerhood; M L Stitzer
Journal:  Am J Drug Alcohol Abuse       Date:  2001-02       Impact factor: 3.829

Review 4.  Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation.

Authors:  M Connock; A Juarez-Garcia; S Jowett; E Frew; Z Liu; R J Taylor; A Fry-Smith; E Day; N Lintzeris; T Roberts; A Burls; R S Taylor
Journal:  Health Technol Assess       Date:  2007-03       Impact factor: 4.014

5.  Behavioral therapy to augment oral naltrexone for opioid dependence: a ceiling on effectiveness?

Authors:  Edward V Nunes; Jami L Rothenberg; Maria A Sullivan; Kenneth M Carpenter; Herbert D Kleber
Journal:  Am J Drug Alcohol Abuse       Date:  2006       Impact factor: 3.829

6.  Opioid antagonism of cannabinoid effects: differences between marijuana smokers and nonmarijuana smokers.

Authors:  Margaret Haney
Journal:  Neuropsychopharmacology       Date:  2006-11-08       Impact factor: 7.853

7.  Effectiveness of low-dose naltrexone in the post-detoxification treatment of opioid dependence.

Authors:  Paolo Mannelli; Ashwin A Patkar; Kathleen Peindl; Heather W Murray; Li-Tzy Wu; Robert Hubbard
Journal:  J Clin Psychopharmacol       Date:  2007-10       Impact factor: 3.153

8.  Problem drinking in relation to treatment outcome among opiate addicts in methadone maintenance treatment.

Authors:  M Stenbacka; O Beck; A Leifman; A Romelsjö; A Helander
Journal:  Drug Alcohol Rev       Date:  2007-01

Review 9.  Sustained-release naltrexone: novel treatment for opioid dependence.

Authors:  Sandra D Comer; Maria A Sullivan; Gary K Hulse
Journal:  Expert Opin Investig Drugs       Date:  2007-08       Impact factor: 6.206

10.  Management of relapse in naltrexone maintenance for heroin dependence.

Authors:  Maria A Sullivan; Fatima Garawi; Adam Bisaga; Sandra D Comer; Kenneth Carpenter; Wilfrid N Raby; Stephen J Anen; Adam C Brooks; Huiping Jiang; Evaristo Akerele; Edward V Nunes
Journal:  Drug Alcohol Depend       Date:  2007-08-02       Impact factor: 4.492

View more
  10 in total

Review 1.  Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives.

Authors:  Paolo Mannelli; Kathleen S Peindl; Tong Lee; Kamal S Bhatia; Li-Tzy Wu
Journal:  Curr Drug Abuse Rev       Date:  2012-03

2.  Agonist-antagonist combinations in opioid dependence: a translational approach.

Authors:  P Mannelli
Journal:  Dipend Patologiche       Date:  2010

Review 3.  Are Alcohol Anti-relapsing and Alcohol Withdrawal Drugs Useful in Cannabinoid Users?

Authors:  Patrycja Kleczkowska; Irena Smaga; Małgorzata Filip; Magdalena Bujalska-Zadrozny
Journal:  Neurotox Res       Date:  2016-08-02       Impact factor: 3.911

4.  Reduced cannabis use after low-dose naltrexone addition to opioid detoxification.

Authors:  Paolo Mannelli; Kathi Peindl; Ashwin A Patkar; Li-Tzy Wu; Chi-Un Pae; David A Gorelick
Journal:  J Clin Psychopharmacol       Date:  2010-08       Impact factor: 3.153

Review 5.  Potential uses of naltrexone in emergency department patients with opioid use disorder.

Authors:  Evan Stuart Bradley; David Liss; Stephanie Pepper Carreiro; David Eric Brush; Kavita Babu
Journal:  Clin Toxicol (Phila)       Date:  2019-03-04       Impact factor: 4.467

6.  Very low dose naltrexone in opioid detoxification: a double-blind, randomized clinical trial of efficacy and safety.

Authors:  Reza Afshari; Majid Khadem-Rezaiyan; Hoda Khatibi Moghadam; Mahdi Talebi
Journal:  Toxicol Res       Date:  2019-11-21

Review 7.  Pharmacological therapies for management of opium withdrawal.

Authors:  Afarin Rahimi-Movaghar; Jaleh Gholami; Laura Amato; Leila Hoseinie; Reza Yousefi-Nooraie; Masoumeh Amin-Esmaeili
Journal:  Cochrane Database Syst Rev       Date:  2018-06-21

Review 8.  Antagonists in the medical management of opioid use disorders: Historical and existing treatment strategies.

Authors:  Adam Bisaga; Paolo Mannelli; Maria A Sullivan; Suzanne K Vosburg; Peggy Compton; George E Woody; Thomas R Kosten
Journal:  Am J Addict       Date:  2018-04

9.  Negative affect-associated drug refusal self-efficacy, illicit opioid use, and medication use following short-term inpatient opioid withdrawal management.

Authors:  Jumi Hayaki; Micah T Conti; Genie L Bailey; Debra S Herman; Bradley J Anderson; Michael D Stein
Journal:  J Subst Abuse Treat       Date:  2021-01-27

10.  Diversity inclusion in United States opioid pharmacological treatment trials: A systematic review.

Authors:  Tessa Nalven; Nichea S Spillane; Melissa R Schick; Lisa L Weyandt
Journal:  Exp Clin Psychopharmacol       Date:  2021-07-05       Impact factor: 3.492

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.